Compare Novartis AG (NVS) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Sony Group Corp — how do they compare? Novartis AG trades at $139.25 (market cap $262.28B), while Sony Group Corp trades at $23.5 (market cap $137.98B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.45%). Which is the better fit depends on your goals.
| NVS | SONY | |
|---|---|---|
Market Cap | $262.28B | $137.98B |
Sector | Health | Technology |
52-Week High | $168.62 | $30.26 |
52-Week Low | $121.80 | $19.32 |
Enterprise Value | $303.60B | $135.82B |
Dividend Yield | 3.45% | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) stock is trading at $137.7, down 13.93% over 24 hours following negative clinical trial news. The technical outlook is bearish with support at $133 and resistance at $138. Fundamentally, the company maintains strong profitability with a 22.5% net income margin and $56.67B revenue in 2025, though recent pipeline setbacks have pressured sentiment. Analyst consensus is mixed with 24% buy ratings but 68% hold, reflecting caution amid growth uncertainties.
The investment outlook is clouded by recent trial failures, but Novartis' solid cash flow and reiterated 5-6% revenue growth guidance through 2030 provide a foundation. Key risks include pipeline execution and competitive threats, while institutional ownership trends will be critical to watch for stability signals. The stock offers value if management can navigate current headwinds effectively.
Sony's stock trades at $23.53, down 4.19% over 24 hours amid bearish technical signals. The company maintains strong operating cash flow of $2.32T for 2025 and beat earnings expectations in two of the last three quarters. However, negative net income margin of -1.75% and projected 2026 net loss of $221.6B raise concerns about near-term profitability despite analyst optimism.
The stock faces headwinds from technical weakness and projected earnings decline, but strong analyst support (68.75% buy ratings) and robust entertainment ecosystem provide long-term potential. Key risks include streaming competition and AI copyright litigation, while valuation metrics remain reasonable with P/E of 19.72 and EV/EBITDA of 7.71.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
